These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37076487)

  • 1. Adaptive data-driven selection of sequences of biological and cognitive markers in pre-clinical diagnosis of dementia.
    Wyss P; Ginsbourger D; Shou H; Davatzikos C; Klöppel S; Abdulkadir A
    Sci Rep; 2023 Apr; 13(1):6406. PubMed ID: 37076487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The TAS Test project: a prospective longitudinal validation of new online motor-cognitive tests to detect preclinical Alzheimer's disease and estimate 5-year risks of cognitive decline and dementia.
    Alty J; Bai Q; Li R; Lawler K; St George RJ; Hill E; Bindoff A; Garg S; Wang X; Huang G; Zhang K; Rudd KD; Bartlett L; Goldberg LR; Collins JM; Hinder MR; Naismith SL; Hogg DC; King AE; Vickers JC
    BMC Neurol; 2022 Jul; 22(1):266. PubMed ID: 35850660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.
    Lombardi G; Crescioli G; Cavedo E; Lucenteforte E; Casazza G; Bellatorre AG; Lista C; Costantino G; Frisoni G; Virgili G; Filippini G
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009628. PubMed ID: 32119112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development, Application, and Results from a Precision-medicine Platform that Personalizes Multi-modal Treatment Plans for Mild Alzheimer's Disease and At-risk Individuals.
    Keine D; Walker JQ; Kennedy BK; Sabbagh MN
    Curr Aging Sci; 2018; 11(3):173-181. PubMed ID: 30338750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.
    Wilcock D; Jicha G; Blacker D; Albert MS; D'Orazio LM; Elahi FM; Fornage M; Hinman JD; Knoefel J; Kramer J; Kryscio RJ; Lamar M; Moghekar A; Prestopnik J; Ringman JM; Rosenberg G; Sagare A; Satizabal CL; Schneider J; Seshadri S; Sur S; Tracy RP; Yasar S; Williams V; Singh H; Mazina L; Helmer KG; Corriveau RA; Schwab K; Kivisäkk P; Greenberg SM;
    Alzheimers Dement; 2021 Apr; 17(4):704-715. PubMed ID: 33480172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling Decline in Cognition to Decline in Function in Alzheimer's Disease.
    Karcher H; Savelieva M; Qi L; Hummel N; Caputo A; Risson V; Capkun G; Alzheimer's Disease Neuroimaging Initiative
    Curr Alzheimer Res; 2020; 17(7):635-657. PubMed ID: 33032508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical judgement by primary care physicians for the diagnosis of all-cause dementia or cognitive impairment in symptomatic people.
    Creavin ST; Noel-Storr AH; Langdon RJ; Richard E; Creavin AL; Cullum S; Purdy S; Ben-Shlomo Y
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD012558. PubMed ID: 35709018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropsychological Decline Improves Prediction of Dementia Beyond Alzheimer's Disease Biomarker and Mild Cognitive Impairment Diagnoses.
    Nation DA; Ho JK; Dutt S; Han SD; Lai MHC;
    J Alzheimers Dis; 2019; 69(4):1171-1182. PubMed ID: 31104015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Internal Consistency Over Time of Subjective Cognitive Decline: Drawing Preclinical Alzheimer's Disease Trajectories.
    Ávila-Villanueva M; Maestú F; Fernández-Blázquez MA
    J Alzheimers Dis; 2018; 66(1):173-183. PubMed ID: 30248053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.
    Davis M; O Connell T; Johnson S; Cline S; Merikle E; Martenyi F; Simpson K
    Curr Alzheimer Res; 2018; 15(8):777-788. PubMed ID: 29357799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Risk of Incident Alzheimer's Disease Dementia in Stable Versus Unstable Patterns of Subjective Cognitive Decline.
    Wolfsgruber S; Kleineidam L; Wagner M; Mösch E; Bickel H; Lϋhmann D; Ernst A; Wiese B; Steinmann S; König HH; Brettschneider C; Luck T; Stein J; Weyerer S; Werle J; Pentzek M; Fuchs A; Maier W; Scherer M; Riedel-Heller SG; Jessen F;
    J Alzheimers Dis; 2016 Oct; 54(3):1135-1146. PubMed ID: 27567852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
    Yu P; Dean RA; Hall SD; Qi Y; Sethuraman G; Willis BA; Siemers ER; Martenyi F; Tauscher JT; Schwarz AJ
    J Alzheimers Dis; 2012; 32(2):373-85. PubMed ID: 22796873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling prognostic trajectories of cognitive decline due to Alzheimer's disease.
    Giorgio J; Landau SM; Jagust WJ; Tino P; Kourtzi Z;
    Neuroimage Clin; 2020; 26():102199. PubMed ID: 32106025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.